Skip to main content

Table 2 Clinical characteristics of the 158 NMIBC patients under surveillance

From: Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer

Characteristic Recurrence-free (n = 86) Recurrence (n = 72)
Age, yrs.
 Median 67 66
 Range 30–84 28–83
Sex, no. (%)
 Male 74 (86.1) 52 (72.2)
 Female 12 (13.9) 20 (27.8)
Smoking History, no. (%)
 Current smoker 25 (29.1) 12 (16.7)
 Former smoker 34 (39.5) 22 (30.6)
 Non-smoker 26 (30.2) 35 (48.6)
 Missing 1 (1.2) 3 (4.1)
Recurrence Rate, no. (%)   72 (45.6)
Time to recurrences, mos.
 Median/Range   10/3–24
Follow-up Urine Analyzed, no. 312 113
Total Urine Analyzed, no. 398 185
Cytology, no. (%)
 Negative/Positive/Suspicious 67 (77.9)/6 (7.0)/2 (2.3) 50 (69.5)/2 (2.8)/3 (4.1)
 Missing 11 (12.8) 17 (23.6)
Tumor Stage, no. (%)
 pTa/pT1/CIS 62 (72.1)/14 (16.3)/4 (4.6) 55 (76.4)/11 (15.3)/2 (2.8)
 Other 6 (7.0) 4 (5.5)
Tumor Grade, no. (%)
 Low/High 48 (55.8)/38 (44.2) 47 (65.3)/25 (34.7)
Risk Categories, no. (%)
 Low/Intermediate/High 23 (26.7)/25 (29.1)/38 (44.2) 15 (20.8)/28 (38.9)/29 (40.3)